Published in Surgery Litigation and Law Weekly, December 29th, 2006
Under the agreement, Bacterin receives a nonexclusive license to Osteotech's U.S. Patent Nos. 5,284,655 and 5,290,558 relating to flowable demineralized bone powder compositions, which are two of the patents that underlie Osteotech's proprietary Grafton DBM line of tissue grafts. These same patents were the subject of litigation in 2001 and were found to be valid by a federal court jury. The agreement also provides Osteotech with option rights to certain Bacterin technology and intellectual property.
Osteotech is a leading provider of human bone and bone...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.